What about this presentation on ovarian function suppression in pre-menopausal and post-menopausal women having Tamoxifen therapy?

Again, this is a very important study. She underlined that one potential difference with other previous studies is the fact that this study took care of identifying women that had regained ovarian function, they had regained ovarian function after chemotherapy. I was very stimulated by the data showing that women under 35, 94 of them regained ovarian function after chemo in that particular group. Again, the addition of exemestane on ovarian suppression was much better than Tamoxifen on ovarian suppression and clearly more beneficial than Tamoxifen alone.

So the message, then, are you convinced that very young women should have ovarian function suppression added to their endocrine therapy?

Based on that study I’m very persuaded, as she said, that I have patients who are committed to ten years of Tamoxifen or have started to use Tamoxifen and I think I’m going to have to have a conversation with them about this data.